THE TAPE

Incyte Genomics Inc

$120.27▼ −0.58%
Last close
Relative strength
65RS
of 99, against every stock▼ -3 on the month
Cooling off
Unconfirmed
+26.1%
six months against the S&P 500
52-week range
−9.3%
from the high
$89.25$132.60
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +14% on a year ago
Why it is on no screen

INCY is off the screens on one check: relative strength.

A base has formed15.8 weeks, from 107.78 to 132.60.
Long enough to count15.8 weeks against 3 needed.
Shallow enough18.7% deep against 35% allowed.
Close to its pivot-9.3% from the pivot; listed down to -20%.
Relative strengthRS 65 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$119.31
-0.8% · tested 4× · last 44 sessions ago
Resistance above
$123.12
+2.4% · tested 7× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Incyte Genomics Inc is not on any of the screens right now. Its relative strength rating is 65, and it sits in Commercial Physical & Biological Research.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+9.7%
Three months against the S&P 500
+1.0%
Six months against the S&P 500
+26.1%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 6.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$6.0B
+14.0% year on year
Operating margin
10.4%
Net margin
6.7%
Free cash flow
$745.0M
3.0% of market cap
Price to sales
4.08×
Price to earnings
60.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
$1.6B
-7.0% QoQ · +14.0% YoY
Gross margin
—
Net income
−$784.8M
Loss
Free cash flow
−$675.3M
Burning · 5q runway

What the numbers say

  • Revenue +14.0% year over year, -7.0% on the quarter
  • Weak: Net loss $785M
  • Weak: Burning cash: operating cash flow -$675M, free cash flow -$675M, worse than $508M last quarter · 5 quarters of cash at this burn
  • Good: Net cash $3.28B · cash $3.28B
Revenue by quarter
Free cash flow
Net income
shares +0.9% in a year · net cash $3.3B

What is not obvious

  • Weak: Stock compensation $70M added back against negative operating cash flow
  • Weak: Interest $605K a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $785M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Earnings comingEvent · 2026-10-28
reports 2026-10-29 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-09-19
5.8 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research · 2026-10-26

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
25
$18,960,424 total

Sold: CAGNONI PABLO J, Mayes Patrick A, Stein Steven H, Issa Mohamed Khairie, Tray Thomas.

Not counted above: 66 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-15 CAGNONI PABLO J · President, Global Head of R&Doption exercise839$60,349
2026-10-15 CAGNONI PABLO J · President, Global Head of R&Doption exercise423$26,124
2026-10-15 CAGNONI PABLO J · President, Global Head of R&Doption exercise455$27,837
2026-10-15 CAGNONI PABLO J · President, Global Head of R&Doption exercise925$59,431
2026-10-15 CAGNONI PABLO J · President, Global Head of R&Dsell2,642$297,780
2026-10-01 Heeson Lee · EVP, Head of Incyte Intlwithheld for tax463$54,236
2026-09-30 BAKER BROS. ADVISORS LP · Director, 10% owneraward322
2026-09-30 Clancy Paul J · Directoraward203$24,634

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy11
Hold14
Sell0
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Incyte Genomics Inc (INCY) — The Tape